LONDON (Reuters) - AstraZeneca’s British clinical trials of its COVID-19 vaccine, one of the most advanced in development, resumed on Monday, according to the European clinical trials database EudraCT.
The trial’s status changed to “restarted” from “temporarily halted”, the database showed.
The move comes after the British drugmaker said on Saturday it had received the green light from safety watchdogs to resume testing.
Reporting by Josephine Mason and Ismail Shakil; editing by Jason Neely
Our Standards: The Thomson Reuters Trust Principles.